9mkf: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
The | ==Rat TRPV2 bound to AV2-1 agonist== | ||
<StructureSection load='9mkf' size='340' side='right'caption='[[9mkf]], [[Resolution|resolution]] 2.83Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[9mkf]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Rattus_norvegicus Rattus norvegicus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9MKF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9MKF FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 2.83Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1BMB:1-[(4~{S})-1-(furan-2-ylsulfonyl)-3,4-dihydro-2~{H}-quinolin-4-yl]cyclopropane-1-carboxylic+acid'>A1BMB</scene>, <scene name='pdbligand=PEX:1,2-DIDECANOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE'>PEX</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9mkf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9mkf OCA], [https://pdbe.org/9mkf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9mkf RCSB], [https://www.ebi.ac.uk/pdbsum/9mkf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9mkf ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/TRPV2_RAT TRPV2_RAT] Calcium-permeable, non-selective cation channel with an outward rectification. Seems to be regulated, at least in part, by growth factors, like IGF1, PDGF and morphogenetic neuropeptide/head activator. May transduce physical stimuli in mast cells. Activated by temperatures higher than 52 degrees Celsius; is not activated by vanilloids and acidic pH (By similarity).<ref>PMID:10201375</ref> <ref>PMID:15249591</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
BACKGROUND AND PURPOSE: Transient receptor potential vanilloid 2 (TRPV2) is a non-selective cation channel implicated in immune cell functions. However, progress in understanding TRPV2 has been limited by a lack of potent and selective pharmacological tools, particularly those targeting the human variant. We aimed to identify and characterise a novel small-molecule activator of TRPV2. EXPERIMENTAL APPROACH: We screened a compound library using Ca(2+) imaging in HEK293 cells stably expressing mouse TRPV2. The lead compound AV2-1 was validated by concentration-response analyses, microfluorometric Ca(2+) assays, and electrophysiological recordings. Structural insights were obtained from cryoEM of TRPV2 in complex with AV2-1, and mutagenesis was performed to confirm binding site residues. The efficacy of AV2-1 was assessed in human peripheral blood-derived macrophages by Ca(2+) imaging, whole-cell electrophysiology and TIRF microscopy to detect Ca(2+) microdomains. KEY RESULTS: AV2-1 is a novel TRPV2 activator showing robust efficacy across mouse, rat and human orthologues. Structural analysis reveals that AV2-1 stabilises the channel in its active conformation by binding to an established intracellular pocket via TRPV2-specific residues His165 and Cys157, as confirmed by mutagenesis experiments. AV2-1 induces TRPV2-dependent global [Ca(2+)](i) signals, ionic currents and localised subplasmalemmal Ca(2+) microdomains in human peripheral blood-derived macrophages. CONCLUSION AND IMPLICATIONS: AV2-1 represents a novel pharmacological tool for probing TRPV2 function in immune cells, combining improved selectivity and potency with low toxicity. Its ability to activate human TRPV2 and elicit physiologically relevant Ca(2+) signals highlights its potential for advancing TRPV2 research and for therapeutic exploration in immune modulation and disease contexts. | |||
Defining AV2-1 as a novel pharmacological probe to target human and rodent TRPV2.,Leipe A, Rocereta JA, Pumroy RA, Leffler A, Schaefer M, Moiseenkova-Bell V, Hill K Br J Pharmacol. 2026 Mar 30. doi: 10.1111/bph.70413. PMID:41913383<ref>PMID:41913383</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 9mkf" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Rattus norvegicus]] | |||
[[Category: Moiseenkova-Bell VY]] | |||
[[Category: Pumroy RA]] | |||
[[Category: Rocereta JA]] | |||